Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model.

Conventional cancer therapies involve the systemic delivery of anticancer agents that neither discriminate between cancer and normal cells nor eliminate the risk of cancer recurrence. Here, we demonstrate that the combination of gene, drug and phototherapy delivered through a prophylactic hydrogel patch leads, in a colon cancer mouse model, to complete tumour remission when applied to non-resected tumours and to the absence of tumour recurrence when applied following tumour resection. The adhesive hydrogel patch enhanced the stability and provided local delivery of embedded nanoparticles. Spherical gold nanoparticles were used as a first wave of treatment to deliver siRNAs against Kras, a key oncogene driver, and rod-shaped gold nanoparticles mediated the conversion of near-infrared radiation into heat, causing the release of a chemotherapeutic as well as thermally induced cell damage. This local, triple-combination therapy can be adapted to other cancer cell types and to molecular targets associated with disease progression.

[1]  G. Sonpavde.  Bevacizumab in colorectal cancer. , 2004, The New England journal of medicine.

[2]  Giusi Moffa,et al.  Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells , 2013, Nature Communications.

[3]  N. Mokhtar,et al.  Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data , 2015, Oncology reports.

[4]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[5]  Xiaohua Huang,et al.  Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. , 2006, Journal of the American Chemical Society.

[6]  N. Artzi,et al.  Natural tissue microenvironmental conditions modulate adhesive material performance. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[7]  M. Stevens,et al.  Engineering nanocomposite materials for cancer therapy. , 2010, Small.

[8]  Aviv Regev,et al.  Comprehensive comparative analysis of RNA sequencing methods for degraded or low input samples , 2013, Nature Methods.

[9]  N. Artzi,et al.  Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance , 2015, Proceedings of the National Academy of Sciences.

[10]  Molly M. Stevens,et al.  Colloidal nanoparticles as advanced biological sensors , 2014, Science.

[11]  Elazer R. Edelman,et al.  Regulation of dendrimer/dextran material performance by altered tissue microenvironment in inflammation and neoplasia , 2015, Science Translational Medicine.

[12]  Martin Vanderlaan,et al.  Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro , 2004, Angiogenesis.

[13]  George A. Calin,et al.  RNAi Therapies: Drugging the Undruggable , 2014, Science Translational Medicine.

[14]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[15]  Michihiro Nakamura,et al.  Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles , 2007, International journal of cancer.

[16]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[17]  W. Wu,et al.  A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[18]  N. Artzi,et al.  Hydrogel Doped with Nanoparticles for Local Sustained Release of siRNA in Breast Cancer , 2015, Advanced healthcare materials.

[19]  Chen-Sheng Yeh,et al.  Gold nanorods in photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. , 2010, Angewandte Chemie.

[20]  N. Artzi,et al.  Aldehyde‐Amine Chemistry Enables Modulated Biosealants with Tissue‐Specific Adhesion , 2009, Advanced materials.

[21]  N. Kaji,et al.  A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[24]  Tzu-Ming Liu,et al.  Synergistic delivery of gold nanorods using multifunctional microbubbles for enhanced plasmonic photothermal therapy , 2014, Scientific Reports.

[25]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[26]  I. Finlay,et al.  Surgical options in the management of advanced and recurrent colorectal cancer. , 2007, Surgical oncology.

[27]  H. Klenk,et al.  Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. , 1981, Virology.

[28]  Dimitrios Chatzopoulos,et al.  Therapy for colorectal cancer. , 2005, The New England journal of medicine.

[29]  Hyun Seok Song,et al.  Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. , 2016, Nature materials.

[30]  Elazer R Edelman,et al.  Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-all-trades in cancer nanotheranostics? , 2014, Advanced drug delivery reviews.

[31]  Michael N. Edmonson,et al.  Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma. , 2014, Cancer genomics & proteomics.

[32]  Shay Artzi,et al.  In vivo and in vitro tracking of erosion in biodegradable materials using non-invasive fluorescence imaging , 2011, Nature materials.

[33]  S. Mocellin.  Microarray technology and cancer gene profiling , 2007 .

[34]  J. Mendell.  miRiad Roles for the miR-17-92 Cluster in Development and Disease , 2008, Cell.

[35]  B. Leggett,et al.  Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival , 2009, British Journal of Cancer.

[36]  M. Bloomston,et al.  Surgical management of colorectal cancer: A review of the literature , 2009, The Indian journal of surgery.

[37]  Neetu Singh,et al.  Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.

[38]  Michael J Sailor,et al.  Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. , 2009, Cancer research.

[39]  C. Strom,et al.  Short stature, digit anomalies and dysmorphic facial features are associated with the duplication of miR-17 ~ 92 cluster , 2014, Molecular Cytogenetics.

[40]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..